Introduction

28
Type 2 diabetes (T2D) is a major component of the metabolic syndrome. It has been shown to 29 affect a growing number of people worldwide. While the etiology of T2D is not fully understood 30 a link with obesity or high abdominal body fat content has been proposed. The role of food 31 proteins in the regulation of serum glucose in humans has been demonstrated in several human 32 intervention studies [for reviews, see: 1, 2, 3] . Human intervention studies with food proteins and 33 food protein hydrolysates have involved a wide range of dietary proteins originating from animal 34 and marine as well as plant sources [4] [5] [6] . However, the mechanism(s) of action explaining the 35 antidiabetic effects observed are currently not fully understood. It is thought that dietary amino 36 acids and short peptides may impact in a number of ways including: (a) the direct stimulation of 37 pancreatic cells leading to increased insulin secretion, (b) inhibition of metabolic enzymes 38 involved in the regulation of serum glucose, such as dipeptidyl peptidase IV (DPP-IV) and -39 glucosidase, and (c) secretion of incretins (i.e., glucose dependent insulinotropic polypeptide 40 (GIP) and glucagon-like peptide-1 (GLP-1)). 41 DPP-IV is an ubiquitous enzyme which has been shown to cleave and inactivate GLP-1 and GIP 42 techniques such as ultrafiltration, solid phase extraction and chromatographic (reverse-phase, 78 cation-exchange, size-exclusion and thin layer) separations, have been used to obtain fractions 79 enriched in more potent DPP-IV inhibitory peptides [16, 18, [25] [26] [27] [28] [29] . 80
Generally, the percentage of DPP-IV inhibition is assessed following incubation of DPP-IV with 81 the peptides/hydrolysates in the presence of a chromogenic substrate (e.g., Gly-Pro-p-nitroanilide 82 (pNA), Gly-Pro-aminomethylcoumarin (AMC) or Gly-Pro-aminoluciferin). Various in vitro 83 protocols, which may vary in terms of the origin of DPP-IV (human recombinant vs. animal 84 extract), nature of the DPP-IV substrate, enzyme to substrate ratio, duration of incubation and pH, 85 have been described in the scientific literature to assess the DPP-IV inhibitory potential of food 86 protein-derived peptides [12] . These differences in experimental conditions may explain, in 87 certain instances, the variations observed for the potency of selected peptide sequences [30] . 88
While most of the in vitro evaluation of DPP-IV inhibitory properties of food protein 89
hydrolysates has been conducted with milk proteins [14, 15, 19, [31] [32] [33] [34] , alternative protein 90 substrates from meat/animal skin [35] [36] [37] [38] , marine [18, 24, [39] [40] [41] and plant [17, [20] [21] [22] [23] [42] [43] [44] [45] ] 91 origin have also been described in the literature. To date, the most potent in vitro DPP-IV 92 inhibitory food protein hydrolysates have been reported for a peptic digest of bovine -93 lactalbumin with an IC 50 of 0.036 mg mL -1 [31] and a simulated gastro-intestinal digest 94 (pepsin/Pancreatin) of Navy beans having an IC 50 of 0.093 mg mL -1 [43] . Differences in DPP-IV 95 inhibition potency between food protein hydrolysates may generally be explained by their unique 96 peptide composition but may also to some extent be dependent on the assay employed [46] . 97
Structure-function of DPP-IV inhibitors
98
Research on DPP-IV inhibitory peptides from food protein sources is relatively novel (< 10 99 years). Therefore, the number of peptide sequences which have been identified to date is limited 100 (< 100 peptide sequences) [12, 33] . 101
Elucidation of the physicochemical characteristics of peptides which are linked to DPP-IV6 inhibition has been attempted. To date, there does not seem to be a consensus for the 103 physicochemical characteristics of peptides which display relatively potent DPP-IV inhibition 104
[47]. However, using a peptide alignment strategy, it has been shown that peptides containing a 105
Trp at the N-terminus and a Pro at position 2 were generally relatively potent DPP-IV inhibitors, 106 having IC 50 values < 200 µM [12] . 107
Several novel peptide sequences have been identified within food protein hydrolysates using 108 liquid chromatography mass-spectrometric (LC-MS) analyses generally coupled with bioactivity-109 driven fractionation approaches [16, 17, 19, 25, 29, 48] . In silico approaches have also allowed 110 the identification of numerous peptide sequences [14, 34, 49, 50] 
Mode of action of dietary DPP-IV inhibitory peptides
115
Different modes of action of DPP-IV inhibitory peptides have been reported. These include 116 competitive, non-competitive, uncompetitive and mixed-type inhibition [14, 17, 27, 50] . 117
Knowledge of the mode of action of DPP-IV inhibitory peptides is important in order to 118 understand their site of interaction with DPP-IV. This information is relevant when studying the 119 molecular docking of peptides to the active site of DPP-IV [47] . 120
In addition to the different modes of inhibition, it has been shown that specific peptides could act 121 hydrolysates [36, 39, 44, 57] . In addition, four animal studies have also demonstrated a reduction8 in plasma DPP-IV activity, which was associated with an increase in the plasma level of active 152 and/or total GLP-1 [36, 39, 44, 57] . 153
To date, the study of DPP-IV inhibition by dietary peptides in humans is in its infancy. A number 154 of studies have analyzed serum DPP-IV activity following nutritional interventions. However, to 155 our knowledge, none of these studies have demonstrated a reduction in DPP-IV activity as a 156 consequence of food-protein or hydrolysate consumption [58] . Interestingly, several fragments 157 from bovine -casein have been reported in the gastrointestinal tract of humans [59] , some of 158 which had previously been described for their in vitro DPP-IV inhibitory properties [60] (Table  159 2). However, to date, clear evidence for the bioavailability of food protein-derived peptides is 160 limited [2] , making it challenging to study their effects on systemic targets. This reinforces the 161 relevance of targeting DPP-IV inhibition directly in the gut as opposed to the serum or other 162 organs. To our knowledge, no study to date has evaluated DPP-IV inhibition directly in the gut of 163 animals or humans in the context of nutritional interventions. 164 
Conclusions and perspectives
